血小板参与了肿瘤发生发展全过程，不断摄取并富集循环中肿瘤特征性的物质而被称为“肿瘤教育血小板（TEP）”，其mRNA表达谱改变已证实可以作为肿瘤标志物，血小板自身剪接行为改变是TEP-mRNA表达谱改变的主要原因。小核RNA(SnRNA)是血小板剪接体的重要组成部分，调节pre-mRNA剪接强度。我们已初步证实，TEP-snRNA在肺癌患者中差异表达具有较好的诊断效能，有望成为新型肺癌诊断标志物。此外，在肿瘤放化疗过程中细胞因凋亡产生的apoEV能富集并能传递应对治疗压力而发生改变遗传物质，引发肿瘤治疗耐受及复发；同时它还能水平传递snRNA调控TEP-snRNA表达，后者表达水平与肿瘤治疗疗效密切相关，因此可作为理想的肿瘤疗效评价标志物。综上所述，在本项目中我们将致力于研究TEP-snRNA在肺癌诊断以及疗效评估中的作用，验证其作为肺癌新型标志物能力；并深入探索肿瘤教育血小板的全过程。

Platelets are involved in the whole process of tumorigenesis and development, constantly absorb and enrich the tumors specified substances in the circulation during their life span, thus called "Tumor Education Platelets" (TEP). The alteration of TEP-mRNA profiling has been identified as tumor markers, which mainly attributes to the change of its splicing behavior. Small nucleus RNA (snRNA), the important component of platelet spliceosome, dominates RNA splicing strength. We have preliminarily confirmed that the differential expression of TEP-snRNA in lung cancer patients, which has excellent diagnostic efficacy with strong potential to become a novel biomarker for lung cancer. Moreover, apoEVs produced from apoptosis are capable to accumulate and transfer snRNA, as well as the bio-substances in response to therapeutic stress during radioand chemotherapy, one of the main factors for cancer treatment tolerance and recurrence. Therefore, the expression level of TEP-snRNA can also reflect the changes of biological information caused by cancer therapy, and act as an ideal marker for therapeutic evaluation. In this project, we will focus on the role of TP-snRNA in the diagnosis and therapeutic evaluation, verify its ability as a new marker for lung cancer, and explore the whole process that cancer educates platelets.